For instance, sorafenib, which can inhibit multiple tyrosine kinases including VEGFR1, VEGFR2, KIT, and PDGFR-α, is widely used in hepatocellular carcinoma (HCC) and renal cell cancer (Bedard et al., 2020). The gene discussed is PDGFRA; the disease is hepatocellular carcinoma.